| scholarly article | Q13442814 |
| P50 | author | David E. Gerber | Q56107235 |
| P2093 | author name string | Sawsan Rashdan | |
| P2860 | cites work | Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer | Q41508440 |
| A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors | Q41699326 | ||
| The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer | Q42382909 | ||
| A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation | Q44242530 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| I-SPY 2--Toward More Rapid Progress in Breast Cancer Treatment | Q51646074 | ||
| Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer | Q52912864 | ||
| Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma | Q54308330 | ||
| Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer | Q54329868 | ||
| Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer | Q56227719 | ||
| Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I | Q78649871 | ||
| NCI-MATCH Trial Draws Strong Interest | Q87328915 | ||
| First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors | Q27851678 | ||
| Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study | Q27851971 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Screening for epidermal growth factor receptor mutations in lung cancer | Q29619696 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine | Q33827699 | ||
| Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs | Q34175045 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. | Q36241287 | ||
| Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400. | Q36303134 | ||
| Bayesian clinical trials | Q36399554 | ||
| ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer | Q36820561 | ||
| The genetics and biology of KRAS in lung cancer | Q37354111 | ||
| Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun | Q38382765 | ||
| MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens | Q38383649 | ||
| P433 | issue | 24 | |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 529 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Annals of Translational Medicine | Q26842362 |
| P1476 | title | Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies | |
| P478 | volume | 4 |
| Q89748317 | A census of pathway maps in cancer systems biology |
| Q64938766 | Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation. |
| Q42331905 | Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies |
| Q64891662 | Learning to Personalize from Practice: A Real World Evidence Approach of Care Plan Personalization based on Differential Patient Behavioral Responses in Care Management Records. |
| Q60444998 | Les essais cliniques en oncologie thoracique à l’ère de la médecine de précision : comment les réaliser en pratique ? |
| Q50195535 | Precision Oncology: The Road Ahead. |
| Q47710730 | Tumor molecular profiling of NSCLC patients using next generation sequencing. |
Search more.